02.06.2012 • News

Teva Chairman Buys 1 Million Shares of Drugmaker

The chairman of Teva Pharmaceutical Industries has purchased 1 million U.S.-listed shares of the world's largest generic drugmaker, the company said on Friday.

Board Chairman Phillip Frost bought the shares on Wednesday, the first day of trading on the New York Stock Exchange. Previously, the U.S.-listed shares of the Israeli company traded on Nasdaq.

Frost bought shares at prices ranging from $37.82 to $39.57, according to the company. The shares were up 0.5% at $39.38 on Friday, moving into positive territory after Teva announced Frost's purchase.

"This investment is simply a reflection of the strength of my conviction regarding Teva's bright future," Frost said in a company-released statement.

Teva, which has a market value of about $38 billion, recently installed Jeremy Levin, a former executive at Bristol-Myers Squibb, as its new chief executive.

 

 

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Free Virtual Event

Batteries and Hydrogen: Competitors or Partners?
CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

most read